

October 12, 2020

NEWS RELEASE

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Securities Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: (0)3-3525-4707

KYORIN assigns Intellectual Properties regarding KRP-203 to Priothera

KYORIN Holdings, Inc. today announced that its wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara, "**Kyorin**") has entered into an asset purchase agreement with Priothera Limited (Head office: Dublin, Ireland, CEO: Florent Gros, "**Priothera**") regarding the intellectual properties of KRP-203, a novel immunomodulator developed by Kyorin.

Under the terms of the agreement, Kyorin will receive considerations including ordinary shares issued by Priothera, for the assignment of the KRP-203 assets such as intellectual rights and drug substance for development. In addition, Kyorin reserves the exclusive license to develop and commercialize KRP-203 in Japan and Korea.

KRP-203 is a novel sphingosine 1 phosphate receptor (S1P receptor) modulator having the action of immunomodulation by reducing egress of lymphocytes from lymph nodes. Kyorin granted Novartis rights to develop and commercialize KRP-203 as a treatment of patients with GvHD (graft-versus-host disease). Novartis terminated its development and returned the license to Kyorin in February 2018. Priothera has now purchased KRP-203 and will develop it in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT). It is expected that KRP-203 would be a more effective and safer agent for AML patients than the existing immunomodulators.

Kyorin is pursuing contribution to health of people around the world by maximizing value of the novel candidate compound discovered in house with rapid global development and by developing original new drugs which meet medical needs.

The impact of the transaction on business performance for the fiscal year ending March 2021 is expected to be negligible.

About Priothera Limited

Foundation: 2020
CEO: Florent Gros

Overview: Priothera is leading the way in developing orally applied sphingosine 1 phosphate receptor modulators for haematological malignancies. S1P receptor modulators have been suggested to largely reduce egress of T cell subsets from lymphatic tissues allowing for dual inhibition of graft-versus-host-disease and enhancing graft-versus-leukemia benefits in patients receiving allogeneic stem cell transplant.

Headquartered in Dublin, Ireland, Priothera was founded in 2020 by Drs. Florent Gros and Dhaval Patel. Joining the founding management team is the experienced industry executive, Dr Simone Seiter.

Founding investors are Fountain Healthcare Partners (Dublin, Ireland), funds managed by Tekla Capital Management, LLC (Boston, Massachusetts), HealthCap (Stockholm, Sweden) and EarlyBird Venture Capital (Berlin, Germany).

About KYORIN Pharmaceutical Co., Ltd.

Foundation: December 1923
President & CEO: Shigeru Ogihara
Annual Sales: JPY 96.336 billion (Fiscal Year ending on March 31, 2020)
Employees: 1,502 (as of March 31, 2020)
Overview:

Trusted among patients and professionals in the medical industry, KYORIN Pharmaceutical strives to be a company that contributes to the public health and is recognized as a one with social significance by improving its presence in the specific therapeutic areas and through global discovery of novel drugs. KYORIN Pharmaceutical uses franchise customer strategy where its marketing efforts are focused on respiratory medicine, otolaryngology and urology. In drug discovery, it is deploying 'selection and concentration' and promoting activities aimed at first-in-class drug discovery, such as actively searching for and introducing external drug discovery themes as well as multi-tiered program development.